Table III.
Cohort | Prognostic subgroup | HR | 95% CI | P |
---|---|---|---|---|
Induction I | t(6;11)/t(10;11) | 5.55 | 2.18–14.17 | <0.001 |
AMKL without t(1;22) | 5.56 | 1.83–16.89 | 0.002 | |
CBF-rearrangement | 0.18 | 0.06–0.59 | 0.004 | |
Age ≥ 10 years | 6.34 | 2.64–15.23 | <0.001 | |
High-dose Ara-C arm | 0.49 | 0.21–1.13 | 0.095 | |
| ||||
Induction II | t(6;11)/t(10;11) | 3.82 | 1.72–8.48 | 0.001 |
AMKL without t(1;22) | 4 | 1.46–10.99 | 0.007 | |
CBF-rearrangement | 0.13 | 0.04–0.39 | <0.001 | |
Age ≥ 10 years | 3.26 | 1.46–7.29 | 0.004 | |
Race (Black) | 2.25 | 1–5.03 | 0.049 | |
Race (Other) | 0.49 | 0.17–1.4 | 0.18 | |
High-dose Ara-C arm | 0.64 | 0.33–1.27 | 0.21 |
HR, hazard ratio; CI, confidence interval; AMKL, acute megakaryoblastic leukaemia; CBF, core-binding factor group of genes; Ara-C, cytarabine.